Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

Fineline Cube Apr 27, 2026
Company Drug

Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design

Fineline Cube Apr 27, 2026
Company Deals

Gilead Sciences Partners with AI Firm Genesis Therapeutics to Develop Novel Small-Molecule Therapies

Fineline Cube Sep 11, 2024

Gilead Sciences Inc. (NASDAQ: GILD), a biopharmaceutical company based in the U.S., has entered into...

Company Deals

Carisma Therapeutics and Moderna Expand Partnership to Target Autoimmune Diseases with CAR-M Therapies

Fineline Cube Sep 11, 2024

Carisma Therapeutics Inc. (NASDAQ: CARM), a U.S.-based company specializing in chimeric antigen receptor (CAR) macrophage...

Company Deals

Itcure Expands Gene Editing Reach with Collaborations in China’s Biotech Sector

Fineline Cube Sep 11, 2024

Itcure, a prominent gene editing specialist headquartered in Suzhou, has announced separate strategic collaborations with...

Company Drug

Qilu Pharmaceutical’s Iruplinalkib Shows Promising Results in Phase II Study for ALK+ NSCLC

Fineline Cube Sep 11, 2024

Qilu Pharmaceutical, a leading pharmaceutical company based in China, has presented updated results from the...

Company Deals

ImmuneOnco Receives Second Payment from Instil Bio, Highlighting Ongoing Licensing Deal

Fineline Cube Sep 11, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the receipt of a further payment...

Company Drug

Nuance Pharma Completes Enrollment for Phase III COPD Trial of Ohtuvayre in China

Fineline Cube Sep 11, 2024

Nuance Pharma, a China-based pharmaceutical company, has announced the completion of patient enrollment for the...

Company Drug

Innovent Biologics Presents Promising Phase I Data for IBI363 in Advanced NSCLC at WCLC

Fineline Cube Sep 11, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has unveiled Phase...

Company Drug

Betta Pharmaceuticals’ MCLA129 for Advanced Solid Tumors Accepted for Review by China’s NMPA

Fineline Cube Sep 11, 2024

Betta Pharmaceuticals Co., Ltd (SHE: 300558), a pharmaceutical company based in China, has announced that...

Company Drug

Duality Biologics Initiates Global Clinical Trial for DB-1419 in Advanced Solid Tumors

Fineline Cube Sep 11, 2024

Duality Biologics, Inc., a biopharmaceutical company based in China, has reached a significant milestone with...

Company Medical Device

Medtronic Secures China Market Approval for Pulsed Electric Field Atrial Fibrillation Treatment Devices

Fineline Cube Sep 11, 2024

Medtronic (NYSE: MDT), the US-Irish medical technology giant, has announced that it has received approvals...

Company Drug Legal / IP

AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute

Fineline Cube Sep 11, 2024

AbbVie Sues BeiGene Over Alleged Trade Secret Theft in BTK Degrader ProgramU.S. pharmaceutical titan AbbVie...

Company Drug

Terns Pharmaceuticals’ Oral GLP-1R Agonist TERN-601 Shows Promising Weight Loss Results in Phase I Trial

Fineline Cube Sep 10, 2024

Terns Pharmaceuticals Inc. (NASDAQ: TERN), a U.S.-based biotechnology company originally spun out from Eli Lilly’s...

Company Drug

GSK’s Nucala Shows Promise in Phase III COPD Trial, MATINEE Results Positive

Fineline Cube Sep 10, 2024

GSK plc (LON: GSK, NYSE: GSK), a leading UK-based pharmaceutical company, has announced positive results...

Company Legal / IP

US House Approves Biosecure Act with Implications for Chinese Biotech Firms

Fineline Cube Sep 10, 2024

The US House of Representatives has taken a decisive step towards tightening biosecurity measures, voting...

Company Drug

CIRC’s Subsidiary HTA Co., Ltd. Secures NMPA Approval for Sodium Fluoride [18F] for Bone Imaging

Fineline Cube Sep 10, 2024

China Isotope & Radiation Corporation’s (CIRC) subsidiary, HTA Co., Ltd. (HKG: 1763), has announced that...

Company Drug

Fosun Pharmaceutical’s Daxxify Receives NMPA Approval for Aesthetic Use in China

Fineline Cube Sep 10, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...

Company Deals

Beijing Centergate Technologies and Bestcomm Pharmaceutical Form Strategic Partnership in Multiple Medical Fields

Fineline Cube Sep 10, 2024

Beijing Centergate Technologies (Holding) Co., Ltd (CENTEK, SHE: 000931), a pharmaceutical manufacturing company in China,...

Company Drug

Jiangsu Hengrui’s ANGPTL3 Inhibitor SHR-1918 Earns Breakthrough Designation for HoFH Treatment

Fineline Cube Sep 10, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals

Chengdu Kanghua Biological Products Inks Five-Year Partnership to Boost Sichuan’s Biotech and Vaccine Industries

Fineline Cube Sep 10, 2024

Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has...

Company Deals

JHM Biopharma Secures Over USD 28 Million in Series B+ Financing to Boost Pipeline Development

Fineline Cube Sep 10, 2024

JHM Biopharma, a protein drug developer based in Hangzhou, has reportedly secured over RMB 200...

Posts pagination

1 … 290 291 292 … 657

Recent updates

  • Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets
  • Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease
  • Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback
  • China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio
  • Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Company

Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease

Company Drug

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.